Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3/IL1β pathway
Background
The protective effect of Coenzyme Q10 (CoQ10) on the cardiovascular system has been reported, however, whether it can promote early recovery of cardiac function and alleviate cardiac remodeling after myocardial infarction (MI) remains to be elucidated. Whether CoQ10 may regulate the macrophage-mediated pro-inflammatory response after MI and its potential mechanism are worth further exploration.
Methods
To determine the baseline plasma levels of CoQ10 by LC-MS/MS, healthy controls and MI patients (n = 11 each) with age- and gender-matched were randomly enrolled. Additional MI patients were consecutively enrolled and randomized into the blank control (n = 59) or CoQ10 group (n = 61). Follow-ups were performed at 1- and 3-month to assess cardiac function after percutaneous coronary intervention (PCI). In the animal study, mice were orally administered CoQ10/vehicle daily and were subjected to left anterior descending coronary artery (LAD) ligation or sham operation. Echocardiography and serum BNP measured by ELISA were analyzed to evaluate cardiac function. Masson staining and WGA staining were performed to analyze the myocardial fibrosis and cardiomyocyte hypertrophy, respectively. Immunofluorescence staining was performed to assess the infiltration of IL1β/ROS-positive macrophages into the ischemic myocardium. Flow cytometry was employed to analyze the recruitment of myeloid immune cells to the ischemic myocardium post-MI. The expression of inflammatory indicators was assessed through RNA-seq, qPCR, and western blotting (WB).
Results
Compared to controls, MI patients showed a plasma deficiency of CoQ10 (0.76 ± 0.31 vs. 0.46 ± 0.10 µg/ml). CoQ10 supplementation significantly promoted the recovery of cardiac function in MI patients at 1 and 3 months after PCI. In mice study, compared to vehicle-treated MI mice, CoQ10-treated MI mice showed a favorable trend in survival rate (42.85% vs. 61.90%), as well as significantly alleviated cardiac dysfunction, myocardial fibrosis, and cardiac hypertrophy. Notably, CoQ10 administration significantly suppressed the recruitment of pro-inflammatory CCR2+ macrophages into infarct myocardium and their mediated inflammatory response, partially by attenuating the activation of the NLR family pyrin domain containing 3 (NLRP3)/Interleukin-1 beta (IL1β) signaling pathway.
Conclusions
These findings suggest that CoQ10 can significantly promote early recovery of cardiac function after MI. CoQ10 may function by inhibiting the recruitment of CCR2+ macrophages and suppressing the activation of the NLRP3/IL1β pathway in macrophages.
Trial registration
Date of registration 09/04/2021 (number: ChiCTR2100045256).
Top-30
Journals
|
1
2
3
|
|
|
International Immunopharmacology
3 publications, 12%
|
|
|
Heliyon
1 publication, 4%
|
|
|
Signal Transduction and Targeted Therapy
1 publication, 4%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 4%
|
|
|
BMC Cardiovascular Disorders
1 publication, 4%
|
|
|
Chemico-Biological Interactions
1 publication, 4%
|
|
|
Journal of Molecular Diagnostics
1 publication, 4%
|
|
|
Pharmaceutical Biology
1 publication, 4%
|
|
|
Phytomedicine
1 publication, 4%
|
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
1 publication, 4%
|
|
|
Apoptosis : an international journal on programmed cell death
1 publication, 4%
|
|
|
Journal of Advanced Research
1 publication, 4%
|
|
|
Tissue and Cell
1 publication, 4%
|
|
|
EMBO Molecular Medicine
1 publication, 4%
|
|
|
Clinical Nutrition
1 publication, 4%
|
|
|
Life Sciences
1 publication, 4%
|
|
|
Drug Design, Development and Therapy
1 publication, 4%
|
|
|
Antioxidants
1 publication, 4%
|
|
|
Frontiers in Cellular and Infection Microbiology
1 publication, 4%
|
|
|
Scientific Reports
1 publication, 4%
|
|
|
Food Science and Nutrition
1 publication, 4%
|
|
|
Journal of Nanobiotechnology
1 publication, 4%
|
|
|
Frontiers in Immunology
1 publication, 4%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
12
|
|
|
Elsevier
12 publications, 48%
|
|
|
Springer Nature
7 publications, 28%
|
|
|
Taylor & Francis
2 publications, 8%
|
|
|
Frontiers Media S.A.
2 publications, 8%
|
|
|
MDPI
1 publication, 4%
|
|
|
Wiley
1 publication, 4%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.